The positive Phase III data de-risks Ris-Rez as a key pipeline asset for GSK, supporting its oncology growth strategy. Traders should watch for upcoming data from the global EMBOLD Sarcoma-202 trial and potential regulatory submissions in China and the US, which could be catalysts for further upside.
Price Chart
Executive Summary
GSK's licensor Hansoh Pharma announced positive Phase III results for risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma, meeting the primary endpoint of progression-free survival. This is the second positive Phase III readout for Ris-Rez, following recent pivotal data in small-cell lung cancer, and strengthens the asset's late-stage profile. The news is a positive pipeline catalyst for GSK's oncology program, though Ris-Rez is still in development and not yet generating revenue, limiting near-term financial impact.
Key Facts
- Hansoh Pharma's ARTEMIS-011 Phase III trial of Ris-Rez met its primary endpoint of progression-free survival in relapsed osteosarcoma.
- Ris-Rez is the only B7-H3-targeted ADC to deliver positive Phase III outcomes across multiple tumor types (osteosarcoma and SCLC).
- GSK holds exclusive global rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
- Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma and relapsed/refractory extensive-stage SCLC.
- GSK is advancing a global Phase Ib/II trial (EMBOLD Sarcoma-202) of Ris-Rez in sarcomas, including osteosarcoma.
Financial Impact
No financial figures disclosed. Ris-Rez is an investigational asset with no current revenue; positive Phase III data supports its pipeline value and potential future regulatory submissions.
Risk Factors
- Ris-Rez is still in clinical development and faces regulatory and commercial risks.
- The osteosarcoma indication is a rare cancer with a small patient population, limiting peak revenue potential.
- Competition from other B7-H3-targeted therapies could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006951 |
| Document: 0001654954-26-006951-index-headers.html | 0001654954-26-006951 |
| Document: 0001654954-26-006951-index.html | 0001654954-26-006951 |
| Document: 0001654954-26-006951.txt | 0001654954-26-006951 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $50.01 $50.22 | ▲ +0.42% | ▼ −0.40% | $47.03 (−5.96%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 14, 2026 18d ago | 6-K | $50.05 $51.08 | ▲ +2.06% | ▲ +1.95% | $47.03 (−6.03%) |
Sep 11, 2026 21d ago | 6-K | $48.13 $50.22 | ▲ +4.34% | ▲ +4.56% | $47.03 (−2.29%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 10, 2026 22d ago | 6-K | $48.12 $51.06 | ▲ +6.11% | ▲ +6.61% | $47.03 (−2.27%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Sep 1, 2026 4w ago | 6-K | $50.66 $48.63 | ▼ −4.01% | ▼ −4.09% | $47.03 (−7.17%) |
Aug 26, 2026 5w ago | 6-K | $51.43 $50.44 | ▼ −1.92% | ▼ −1.80% | $47.03 (−8.56%) |
Aug 24, 2026 5w ago | 6-K | $51.78 $50.25 | ▼ −2.95% | ▼ −3.42% | $47.03 (−9.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access